RBC Capital analyst Leonid Timashev raised the firm’s price target on Nuvation Bio (NUVB) to $12 from $9 and keeps an Outperform rating on the shares. The firm updated models for several biotech companies after meeting with managements.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB: